09:10 AM EST, 02/12/2026 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Thursday that its drug infigratinib as a potential treatment for children with achondroplasia met its primary endpoint of improving annualized height velocity in a late-stage clinical trial.

The drug also showed "statistically significant" improvements in secondary endpoints of body proportionality and absolute height compared with placebo, the company said.

Achondroplasia, a common form of dwarfism, is a rare genetic condition.

In the study, which involved children aged 3 to 8 years old, the drug was well-tolerated with no patients dropping out and no serious adverse reactions, the company said.

BridgeBio said it plans to meet with regulatory authorities to discuss the submission of a new drug application and marketing authorization application for infigratinib in H2.

Shares of the company were up 15% in recent Thursday premarket activity.